Hemostasis-related platelet receptors and pathways

Hemostasis-related platelet receptors and pathways encompass a diverse set of molecular targets essential for blood clot formation and vascular integrity (StatPearls, NBK537061). This category includes key proteins such as the P2Y12 purinergic receptor, Glycoprotein IIb/IIIa (Integrin alpha-IIb/beta-3), Cyclooxygenase-1 (COX-1), and Protease-activated receptor-1 (PAR-1) (PubMed, 28253701). These components work in concert to mediate platelet adhesion, activation, and aggregation in response to vascular injury (UniProt, Q9H244). While vital for preventing blood loss, overactivation of these pathways leads to pathological thrombosis, which is the underlying cause of myocardial infarction and ischemic stroke (NIH, Cardiovascular Diseases). Antiplatelet drugs target these specific receptors and enzymes to reduce the risk of cardiovascular events in high-risk patients (PubChem, Aspirin). Understanding these pathways is crucial for balancing the prevention of thrombosis with the inherent risk of bleeding associated with therapy (PubMed, 30103107).

Other names

Platelet activation pathwaysPlatelet aggregation receptorsHemostatic signaling cascades

Inhibition of cyclooxygenase-1 (COX-1) to prevent thromboxane A2 synthesis; antagonism of P2Y12 purinergic receptors to block ADP-induced activation; inhibition of Glycoprotein IIb/IIIa receptors to prevent fibrinogen binding; and antagonism of Protease-activated receptor-1 (PAR-1) to block thrombin-mediated activation (StatPearls, NBK537061).